TCG Crossover Management, LLC
CIK 1839948 · View on SEC EDGAR ↗
- Portfolio value
- $4.2B
- Positions
- 54
- As of
- June 30, 2026
#915 of 9,443 by 13F value · top 9.7%
Portfolio value QoQ: +19.0% 13F does not disclose cash
- Top 10 holdings weight
- 57.45%
- Top 25 holdings weight
- 85.79%
- Positions above 1%
- 26
- Effective number of positions
- 16.2
Based on 13F long-equity holdings only (cash, bonds, shorts not disclosed)
Turnover Q2 2026: 12.41% Est. buys $475,122,092 · sells $492,418,484
Median holding: 3.0 quarters Tracked Q4 2024–Q2 2026 · 64.3% still held
- New positions
- 12
- Increased
- 2
- Decreased
- 9
- Closed
- 7
On this page
- Performance vs S&P How this manager's 13F portfolio performed against the S&P 500.
- Sector breakdown How the portfolio splits across market sectors.
- Portfolio Every stock this institution reports holding, from its latest 13F.
- Biggest new bets Brand-new positions opened in the latest quarter.
- Top moves The biggest position increases and decreases this quarter.
- Exited positions Positions the manager fully sold out of last quarter.
Performance vs S&P 500
Annualized: +134.0% · S&P 500: +18.0%
Approximates a buy-and-hold portfolio built from quarterly SEC 13F snapshots. Excludes cash, short positions, options/derivatives, and non-13(f) securities — reflects the disclosed long-equity book only, not total fund AUM. SEC filing lag is up to 45 days; this is not a real-time-copyable timing.
Priceable coverage: 97.8% · Options excluded: 0.0%
Sector breakdown
Healthcare
96.5%
Other/Unmapped
3.5%
Full portfolio 54 positions
| Type | Streak | 8Q trend | |||||
|---|---|---|---|---|---|---|---|
| ABVX Abivax SA - American Depositary Shares | $800,603,959 | 19.24% | 6,007,834 | $78,935,144 | Down ×2 | ||
| TNGX Tango Therapeutics, Inc. - Common Stock | $283,878,343 | 6.82% | 9,081,201 | $63,568,338 | Down ×2 | ||
| CGON CG Oncology, Inc. - Common stock | $260,768,136 | 6.27% | 3,670,206 | $12,368,594 | |||
| COGT Cogent Biosciences, Inc. - Common Stock | $187,866,673 | 4.52% | 4,854,436 | $-2,539,277 | Down ×4 | ||
| IMVT Immunovant, Inc. - Common Stock | $171,766,278 | 4.13% | 4,457,988 | $61,029,856 | |||
| SYRE Spyre Therapeutics, Inc. - Common Stock | $168,733,670 | 4.06% | 1,900,582 | $72,868,314 | |||
| DNTH Dianthus Therapeutics, Inc. - Common Stock | $163,437,308 | 3.93% | 1,676,624 | $22,735,022 | |||
| MIRM Mirum Pharmaceuticals, Inc. - common stock | $124,334,076 | 2.99% | 1,062,049 | $26,221,989 | |||
| ZLAB Zai Lab Limited - American Depositary Shares | $116,614,913 | 2.80% | 6,137,627 | Up ×1 | |||
| AMLX Amylyx Pharmaceuticals, Inc. - Common Stock | $112,138,864 | 2.70% | 6,243,812 | $25,349,877 | |||
| GLUE Monte Rosa Therapeutics, Inc. - Common Stock | $111,856,054 | 2.69% | 4,622,151 | $35,821,670 | |||
| BCRX BioCryst Pharmaceuticals, Inc. - Common Stock | $110,209,680 | 2.65% | 11,020,968 | $5,290,065 | |||
| VOR Vor Biopharma Inc. - Common Stock | $104,441,366 | 2.51% | 5,673,078 | $7,942,314 | |||
| TYRA Tyra Biosciences, Inc. - Common Stock | $103,772,421 | 2.49% | 3,248,980 | $-20,663,513 | |||
| DYN Dyne Therapeutics, Inc. - Common Stock | $102,502,348 | 2.46% | 4,615,144 | $18,829,787 | |||
| IRON Disc Medicine, Inc. - Common Stock | $98,143,787 | 2.36% | 1,341,862 | $12,345,131 | |||
| RLAY Relay Therapeutics, Inc. - Common Stock | $79,954,491 | 1.92% | 4,273,356 | $37,434,599 | |||
| SVRA Savara, Inc. - Common Stock | $76,151,183 | 1.83% | 12,362,205 | $8,653,544 | |||
| AURA Aura Biosciences, Inc. - Common Stock | $67,686,664 | 1.63% | 9,533,333 | Up ×1 | |||
| RVMD Revolution Medicines, Inc. - Common Stock | $63,843,565 | 1.53% | 340,899 | $7,781,566 | Down ×1 | ||
| Unknown issuer (CUSIP: 337185102) | $58,253,516 | 1.40% | 2,895,304 | Up ×1 | |||
| KOD Kodiak Sciences Inc - Common Stock | $56,318,161 | 1.35% | 1,445,538 | $1,214,253 | |||
| AVTX Avalo Therapeutics, Inc. - Common Stock | $55,756,378 | 1.34% | 3,017,120 | $44,732,320 | Up ×2 | ||
| LBRX LB Pharmaceuticals Inc - Common Stock | $46,972,446 | 1.13% | 1,447,310 | $1,692,835 | Down ×1 | ||
| IPSC Century Therapeutics, Inc. - Common Stock | $43,401,690 | 1.04% | 17,754,430 | $4,380,116 | |||
| TECX Tectonic Therapeutic, Inc. - Common Stock | $41,418,128 | 1.00% | 1,204,891 | $4,174,947 | |||
| XNCR Xencor, Inc. - Common Stock | $39,479,422 | 0.95% | 2,452,138 | $9,906,638 | |||
| SRZN Surrozen, Inc. - Common Stock | $38,226,971 | 0.92% | 1,473,101 | $-4,684,461 | |||
| EDIT Editas Medicine, Inc. - Common Stock | $36,000,000 | 0.87% | 11,111,111 | Up ×1 | |||
| MBX MBX Biosciences, Inc. - Common Stock | $35,880,000 | 0.86% | 650,000 | $16,477,500 | |||
| PHVS Pharvaris N.V. - Ordinary Shares | $34,864,559 | 0.84% | 1,008,229 | Up ×1 | |||
| SLN Silence Therapeutics Plc - American Depository Share | $33,308,489 | 0.80% | 3,033,560 | $17,321,628 | |||
| IFRX InflaRx N.V. - Common Stock | $32,480,000 | 0.78% | 14,500,000 | Up ×1 | |||
| ALT Altimmune, Inc. - Common Stock | $30,400,000 | 0.73% | 10,000,000 | Up ×1 | |||
| JANX Janux Therapeutics, Inc. - Common Stock | $27,488,517 | 0.66% | 1,789,617 | $2,612,841 | |||
| CATX | $26,992,083 | 0.65% | 7,915,567 | $-6,015,831 | |||
| AGMB AgomAb Therapeutics NV - ADRs representing one common share. | $26,650,964 | 0.64% | 2,053,233 | $5,112,550 | |||
| BHVN Biohaven Ltd. Common Shares | $26,485,686 | 0.64% | 1,779,952 | $-12,695,256 | Down ×1 | ||
| AKTS Aktis Oncology, Inc. - Common stock | $22,450,129 | 0.54% | 696,560 | Up ×1 | |||
| ALEC Alector, Inc. - Common Stock | $20,100,000 | 0.48% | 10,000,000 | $-1,400,000 | |||
| FBRX Forte Biosciences, Inc. - Common Stock | $19,550,000 | 0.47% | 920,000 | Up ×1 | |||
| MNPR Monopar Therapeutics Inc. - Common Stock | $18,826,047 | 0.45% | 203,327 | $11,588,124 | Up ×1 | ||
| OCUL Ocular Therapeutix, Inc. - Common Stock | $16,180,925 | 0.39% | 1,647,752 | $2,224,466 | |||
| ADCT ADC Therapeutics SA Common Shares | $12,187,487 | 0.29% | 11,390,175 | $-30,525,669 | |||
| ALXO ALX Oncology Holdings Inc. - Common Stock | $11,706,858 | 0.28% | 5,655,487 | $-14,381,899 | Down ×1 | ||
| TRDA Entrada Therapeutics, Inc. - Common Stock | $7,803,293 | 0.19% | 1,060,230 | $-21,064,957 | Down ×1 | ||
| CGEM Cullinan Therapeutics, Inc. - Common Stock | $7,407,573 | 0.18% | 406,786 | $1,627,144 | |||
| ARVN Arvinas, Inc. - Common Stock | $5,875,984 | 0.14% | 707,098 | $-19,431,103 | Down ×2 | ||
| KRRO Korro Bio, Inc. - Common Stock | $5,486,847 | 0.13% | 416,301 | $774,320 | |||
| Unknown issuer (CUSIP: G75226103) | $5,350,000 | 0.13% | 500,000 | Up ×1 | |||
| LONA LeonaBio, Inc. - Common Stock | $4,267,818 | 0.10% | 464,398 | $-398,778 | |||
| Unknown issuer (CUSIP: G50765109) | $2,272,000 | 0.05% | 200,000 | Up ×1 | |||
| CNTX Context Therapeutics Inc. - Common Stock | $1,485,945 | 0.04% | 2,682,696 | $-5,542,719 | |||
| EIKN Eikon Therapeutics, Inc. - Common Stock | $494,621 | 0.01% | 37,902 | Up ×1 | |||
| No matches | |||||||
Biggest new bets
New positions opened this quarter, largest first.
| Security | Value | Shares | % of portfolio |
|---|---|---|---|
| ZLAB | $116,614,913 | 6,137,627 | 2.80% |
| AURA | $67,686,664 | 9,533,333 | 1.63% |
| Unknown issuer (CUSIP: 337185102) | $58,253,516 | 2,895,304 | 1.40% |
| EDIT | $36,000,000 | 11,111,111 | 0.87% |
| PHVS | $34,864,559 | 1,008,229 | 0.84% |
| IFRX | $32,480,000 | 14,500,000 | 0.78% |
| ALT | $30,400,000 | 10,000,000 | 0.73% |
| AKTS | $22,450,129 | 696,560 | 0.54% |
| FBRX | $19,550,000 | 920,000 | 0.47% |
| Unknown issuer (CUSIP: G75226103) | $5,350,000 | 500,000 | 0.13% |
| Unknown issuer (CUSIP: G50765109) | $2,272,000 | 200,000 | 0.05% |
| EIKN | $494,621 | 37,902 | 0.01% |
Top movers (QoQ)
| Security | Action | Shares Δ | Value Δ |
|---|---|---|---|
| ABVX | Trimmed | -473K | +$78.9M |
| SYRE | Price move only | +0 | +$72.9M |
| TNGX | Trimmed | -1.4M | +$63.6M |
| IMVT | Price move only | +0 | +$61.0M |
| RLAY | Price move only | +0 | +$37.4M |
| GLUE | Price move only | +0 | +$35.8M |
| ADCT | Price move only | +0 | -$30.5M |
| MIRM | Price move only | +0 | +$26.2M |
| AMLX | Price move only | +0 | +$25.3M |
| DNTH | Price move only | +0 | +$22.7M |
1 position hidden (data completeness check)
Exited positions
Includes corporate events (mergers, delistings) — not all exits are sells
Closed positions reflect 13F reporting changes; for index managers these are often mechanical (delisting, M&A, index rebalancing), not active decisions.
| Security | Quarter | Shares before | Value before | Price since exit |
|---|---|---|---|---|
| CNTA | June 30, 2026 | 4,286,480 | $170,258,986 | No longer tracked |
| RAPT | March 31, 2026 | 2,582,408 | $87,466,159 | No longer tracked |
| EYPT | March 31, 2026 | 3,572,335 | $65,266,560 | -53.8% |
| TRML | Dec. 31, 2025 | 1,311,783 | $62,742,581 | No longer tracked |
| CDTX | Sept. 30, 2025 | 1,005,901 | $48,997,438 | No longer tracked |
| FULC | June 30, 2026 | 5,250,000 | $40,267,500 | 7.2% |
| MLYS | June 30, 2025 | 2,470,265 | $39,227,808 | 102.0% |
| AGIO | March 31, 2026 | 1,181,841 | $32,169,712 | 4.7% |
| IRON | Dec. 31, 2025 | 465,257 | $30,744,183 | 1.8% |
| ATXS | Dec. 31, 2025 | 2,761,861 | $20,106,348 | No longer tracked |
| SLNO | Sept. 30, 2025 | 186,250 | $15,604,025 | No longer tracked |
| LQDA | June 30, 2026 | 403,048 | $15,211,032 | -7.4% |
| CMPS | June 30, 2025 | 3,858,000 | $11,033,880 | 397.9% |
| THRD | Sept. 30, 2025 | 1,915,424 | $10,400,752 | No longer tracked |
| ELVN | Sept. 30, 2025 | 498,000 | $9,989,880 | 188.1% |
| KROS | March 31, 2025 | 550,000 | $8,706,500 | 6.6% |
| ADVM | Dec. 31, 2025 | 1,668,174 | $7,556,828 | No longer tracked |
| URGN | June 30, 2026 | 405,365 | $7,288,463 | 34.6% |
| MAZE | March 31, 2026 | 173,816 | $7,201,197 | -0.3% |
| NKTR | Sept. 30, 2025 | 266,666 | $6,890,649 | 33.4% |
| GPCR | June 30, 2026 | 140,411 | $6,767,810 | 0.0% |
| AVTE | June 30, 2025 | 2,240,809 | $5,624,431 | No longer tracked |
| PEPG | Dec. 31, 2025 | 1,200,000 | $5,544,000 | -55.5% |
| KURA | Sept. 30, 2025 | 735,184 | $4,242,012 | 43.8% |
| VTYX | March 31, 2026 | 316,195 | $2,855,241 | No longer tracked |
| UPB | June 30, 2026 | 181,063 | $1,629,567 | 1.6% |
| VTGN | June 30, 2026 | 2,676,580 | $1,529,665 | 5.2% |
| JBIO | Sept. 30, 2025 | 64,023 | $639,590 | 168.8% |
| CABA | Sept. 30, 2025 | 86,795 | $131,928 | 37.0% |